anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Healthy women who are pregnant with their first child will be included in the study. Information about their general health will be gathered. These women will be screened for pelvic disorders at the start and end of study. Three-dimensional ultrasound will be performed three times: 12-24 weeks, 34-39 weeks and 4-6 weeks after delivery. Fetal measurements will be included in the third trimester ultrasound for prediction of estimated birth weight. The relationship of the predicted fetal weight and the likelihood of having a successful vaginal delivery will be studied. Images will be analyzed for pelvic muscles function and injuries. Information regarding the length of labor, types of delivery and vaginal tears will be gathered. The information obtained will be analyzed to look for the strength of correlation of variables to the outcomes.
A thiazole compound as a PPARdelta(peroxisome proliferator activated receptor delta) ligand is provided to be used for treating obesity, hyperlipidemia, arteriosclerosis, diabetes, dementia, Alzheimer's and Parkinson's disease and for strengthening muscles or improving memory. A thiazole compound is represented by a formula(1). A pharmaceutical composition for preventing and treating arteriosclerosis, hyperlipidemia, diabetes, obesity, dementia, Alzheimer's disease or Parkinson's disease or for increasing the level of high density lipoprotein(HDL) or for enhancing endurance comprises the thiazole compound or a pharmaceutically acceptable salt thereof as an effective ingredient. A health food adjuvant or health beverage comprises the thiazole compound or a pharmaceutically acceptable salt thereof as an effective ingredient. A food additive or an animal feed or functional cosmetic composition comprises the thiazole compound or a pharmaceutically acceptable salt thereof. A PPARdelta activator composition comprises the thiazole compound or a pharmaceutically acceptable salt thereof.
PURPOSE: A TLR8 siRNA and a composition containing the same for treating atopic dermatitis are provided to enhance IFN-gamma expression and to suppress IgE immune response. CONSTITUTION: A TLR8 siRNA suppresses TLR8 expression and has a base of sequence number 2. A recombinant vector contains a gene transcribing siRNA. A composition for treating atopic dermatitis contains the recombinant vector as an active ingredient. The composition contains a bacterial cell which is transformed by the recombinant vector as an active ingredient. The bacterial cell is Salmonella typhimurium.
Tarceva administered on continuous oral dosing schedule at 150 mg/day for pts not on EIAEDs \& 450 mg/day for pts on EIAEDs. Starting dose level of dasatinib will be 100 mg once day via continuous oral daily dosing. Dasatinib will be increased in successive cohorts of enrolled pts. Pts will remain on treatment until excessive toxicity, progressive disease, withdrawal of consent/death.

Pts have confirmed diagnosis of recurrent/progressive WHO gr IV MG / WHO grade III MG. Phase I 3+3 dose escalation design w 2 independently escalated stratum: stratum A-pts not on CYP3A-enzyme inducing anti-epileptic drugs; stratum B-pts on EIAEDs. Assessment of safety will be based mainly on frequency of adverse events, particularly adverse events leading to discontinuation of treatment \& on number of significant lab abnormalities.
The utility model discloses a tooth bead, which is prepared by preparing toothpaste into granular bodies, and coating sugar coat on the outer layer of the tooth bead to solidify into soft granular bodies. The utility model discloses make into toothpaste behind the pearl of tooth and form the four seasons toothpaste of different colours, use the pearl of tooth at every turn, do not direct earlier contact the toothbrush, contain the pearl of tooth in the oral cavity and reuse the toothbrush when brushing teeth, prevent cross infection. The dental bead is convenient to carry, does not need plastic original toothpaste hose packaging, and can be independently packaged or packaged in multiple or in any packaging form which accords with food sanitation and safety. Solidifying the dental beads changes the past tooth brushing habit of an individual, firstly putting the dental beads into the oral cavity, then using the toothbrush, brushing the teeth consistently with the past tooth brushing, and rinsing the mouth with water after brushing. The multifunctional dental bead is convenient to use in all seasons. The toothpaste body is coated with sugar coating which is non-sticky, and the teeth beads are mixed and packed without sticking together.
Investigators will conduct a Stage 1 pilot feasibility study at McLean Hospital to begin to evaluate Epidiolex as a pharmacotherapy for adults with cannabis use disorder. In this randomized, double-blind, placebo-controlled trial, cannabis-dependent subjects ages 18-65 will receive medical management over a 6-week period, with half receiving Epidiolex treatment and half receiving placebo. Participants will receive either up to 800 mg Epidiolex or placebo over a 6-week treatment period. Following treatment completion, participants will have a follow-up visits at 10 and 14 weeks. Primary outcomes will include self-report of cannabis smoking and results of quantitative urine drug screens for cannabis. Secondary outcome measures will include treatment retention, patient satisfaction, cannabis withdrawal, cannabis craving, depressive symptoms, anxiety symptoms, compliance, and cigarette use.
In recent work performed by the University of Arizona Cancer Center team, 59 patients with a known diagnosis of a solid tumor malignancy on active immunosuppressive cancer therapy were enrolled through the University of Arizona Cancer Center during their routine care. These subjects had a decreased response with the vaccine when compared to the health cohort. The investigators are amending this study to explore the effects on immune response to include a potential third vaccine for the cancer cohort. This will increase the visits required to approximately two more visits. It will require two additional blood samples, one 48 hours prior to third vaccine and the second, 5-11 days after the third vaccine. The following protocol will be for the subjects that decide to continue onto a third vaccination.
Russian Snow White (RSW) chickens are characterized by high egg production, extreme resistance to low temperatures, disease resistance, and by the snow-white color of the day-old chicks. Studying the genome of this unique chicken breed will reveal its evolutionary history and help to understand the molecular genetic mechanisms underlying the unique characteristics of this breed, which will open new breeding opportunities and support future studies. We have sequenced and made a de novo assembly of the whole RSW genome using deep sequencing (250×) by the short reads. The genome consists of 40 chromosomes with a total length of 1.1 billion nucleotide pairs. Phylogenetic analysis placed the RSW near the White Leghorn, Fayoumi, and Houdan breeds. Comparison with other chicken breeds revealed a wide pool of mutations unique to the RSW. The functional annotation of these mutations showed the adaptation of genes associated with the development of the nervous system, thermoreceptors, purine receptors, and the TGF-beta pathway, probably caused by selection for low temperatures. We also found adaptation of the immune system genes, likely driven by selection for resistance to viral diseases. Integration with previous genome-wide association studies (GWAS) suggested several causal single nucleotide polymorphisms (SNPs). Specifically, we identified an RSW-specific missense mutation in the RALYL gene, presumably causing the snow-white color of the day-old chicks, and an RSW-specific missense mutation in the TLL1 gene, presumably affecting the egg weight.
As many as a third of the nearly 700,000 military personnel deployed during Desert Shield and Desert Storm (Aug 2, 1990 to July 31, 1991) in the Kuwaiti Theater of Operations are suffering from Gulf War Illness (GWI), an unexplained chronic illness characterized by multiple symptoms. Gulf War Veterans experienced environmental exposures that are known to be oxidative stressors which contribute to cell injury, resulting in mitochondrial dysfunction Exploratory studies using interventions that support cell functioning and prevent or repair stress mediators suggest a role for these targeted interventions, such as Coenzyme Q10. The goal of this clinical trial is to determine if Coenzyme Q10 is effective in increasing physical functioning for Veterans with Gulf War Illness.

This is a randomized, two group, double blind, placebo controlled, Phase III clinical trial. The treatment group will receive a (2x200 mg for 2 months and 1x200 mg for 4 months) once a day of ubiquinol for 6 months. The placebo group will receive matching placebo (2x200 mg for 2 months and 1x200 mg for 4 months) once a day of ubiquinol for 6 months. The primary outcome measure for this clinical trial is a change from baseline of SF-36, with respect to physical functioning and symptoms. The secondary outcome measures include changes from baseline of peripheral blood levels of biomarkers, and of GWI-associated symptoms of chronic pain, fatigue, sleep issues, and cognitive impairment.
A plant extract mixture for peeling corneum according to the present invention comprises extracts extracted from raw ingredients including mume fruits, hawthorn fruits, cranberry tree fruits, and Chaenomeles lagenaria fruits by using a solvent. It is preferable that the raw ingredients include 10-70 parts by weight of each of mume fruits, hawthorn fruits, cranberry tree fruits, and Chaenomeles lagenaria fruits. More preferably, the mume fruits, the hawthorn fruits, the cranberry tree fruits, and the Chaenomeles lagenaria fruits are mixed at a weight ratio of 2:1:4:1. It is preferable that an extraction solvent used according to the present invention is one or more components selected from the group consisting of refined water, butyleneglycol solution, and propyleneglycol solution. It is preferable that the plant extract mixture for peeling corneum according to the present invention contains tartaric acid having a concentration of 1,000-2,000 ppm. By using the produced plant extract mixture for peeling corneum, cosmetic liquid (skin lotion) and cosmetic cream (nutritional lotion, nutritional cream, or massage cream) can be produced.
The method comprises (a) forming a spray of a compsn. comprising (i) a soluble vitamin-mineral, (ii) a soluble flavouring agent and (iii) a non-toxic solvent for the vitamin and the flavouring agent; (b) spraying the spray compsn. into the oral cavity to provide an aliquot dose of the vitamin-mineral and (c) repeating the aliquot dose at spaced intervals during waking hrs. to provide a predetermined pharmacologically effective total dose. The compsn. pref. includes a non-toxic zinc cpd. The vitamin may be e.g. Vitamin A, Vitamin B12 or Vitamin C. Also claimed is a spray compsn. comprising (i) a soluble vitamin-mineral, (ii) a soluble flavouring agent and (iii) a non-toxic solvent for the vitamin and the flavouring agent.
In Part 2, pegsitacianine the single dose of 1 mg/kg of given 6-100 hours prior to surgery will be used to in patients with unknown primary cancer of the head and neck. These patients typically undergo exam under anesthesia with a laryngoscopy as well as panendoscopy for identifying the source of the metastatic cancer found in the cervical nodes. The diagnostic performance of pegsitacianine fluorescence imaging for detecting primary tumors and metastatic lymph nodes in these patients will be evaluated. All the available data to date will be used to decide the additional tumor type(s), number of patients per tumor type, and number of Group(s) to be enrolled.
Antibiotics have long been used at sub-therapeutic levels to control incidences of post-weaning diarrhea and to improve growth performance in pigs. However, the current trend world-wide is to eliminate the use of in-feed antibiotics due to increased public concerns over the spread of antibiotic resistance in bacterial pathogens, which poses a threat to public health. Alternatives to in-feed antibiotics are needed. Thymol essential oil exhibits strong in vitro antibacterial activity; however; direct inclusion of essential oils to pig feeds has limited efficacy due to their high volatility, low stability during feed processing, interactions with other feed components and poor availability in lower gut. To solve these problems, we developed lipid matrix beads using thymol and a fatty acid with incorporation of 2% polysaccharides via a melt-granulation technique. Laurie acid was identified as a suitable carrier for thymol. In vitro release of thymol from lipid matrix granules was determined using simulated salivary fluid (SSF), simulated gastric fluid (SGF) and simulated intestinal fluid (SIF), respectively. The lipid matrix granules with 2% polysaccharides exhibited a slow release rate (%) of essential oil and fatty acid in SSF (21.2±2.3; 36±1.1), SGF (73.7±6.9; 54.8±1.7) and SIF (99.1±1.2; 99.1±0.6), respectively. However, the lipid matrix granules without polysaccharides had quick release (%) of essential oil and fatty acid from the SSF (79.9±11.8; 84.9±9.4), SGF (92.5±3.5; 75.8±5.9) and SIF (93.3±9.4; 93.3±4.6), respectively.
NEW MATERIAL:A compound expressed by formula I [X1 is halogen; X2 is H or X1; Y1 is CH2-CH2, CO-CH2, CH=CH or CidenticalC; Y2 is CH2-CH2 or CH=CH; R1 is H or alkyl; R2 is single bond or alkylene; R3 is (halogen-substituted) alkyl, (alkyl-substituted) cycloalkyl or monocyclic aryl or monocyclic aryloxy which may be respectively substituted with halogen or haloalkyl] or salts thereof. EXAMPLE:17-(RS)-Fluoro-13,14-dihydro-15-keto-PGE2 methyl ester. USE:Useful as a PGE derivative capable of selectively exhibiting acting of the PGE, e.g. with some of PEG actions deteriorated or deficient in spite of cerebral function improving action thereof. PREPARATION:A Corey lactone, expressed by formula II and having a suitable protecting group is oxidized and then reacted with a compound expressed by formula III to introduce an omega-chain thereinto. Thereby, a compound expressed by formula IV is obtained and a compound expressed by formula V is then derived therefrom. An alpha-chain is introduced into the aforementioned compound to afford a compound expressed by formula VI. The objective compound expressed by formula I is obtained from the above-mentioned compound expressed by formula VI.
A soluble polymeric metal complex comprises a transition Gp. IB, VIIB or VIIIB metal ion bonded covalently to a tetra-dentate polymer ligand. The metal ion has >=1 other ligand bonded axially to it and the polymer may be natural or (semi)-synthetic. Pref. polymers are water soluble having functional NH2, OH or carboxy gps. e.g. polyethers e.g. polyethylene glycol, dextrans, chemically modified proteins, polysaccharides, polyamino acids, PVA, PVP, polyurethanes, poly(meth)acrylic acid, polyethylene imine etc. The complexes can be used as reversible oxygen carriers to improve the oxygen concn. of solns. They may be used as blood substitute, in fuel cells, oxidation reactions as catalysts and in oxygen production.
SARS-CoV-2 is a virus of the coronavirus family, which includes a large number of viruses that can cause a wide variety of diseases in humans. The SARS-CoV-2 virus causes acute symptoms associated with the infection and can cause chronic conditions known as Post-COVID. To understand the prevalence and variety of Post-COVID a large observational study of health insurance data from Germany was set up. The exposed patients were identified by a diagnosis indicating a confirmed laboratory test for COVID.

The basic question concerns the burden of the Post-COVID condition. The study investigate which symptoms are more common in humans after the exposure to the virus compared to a matched unexposed cohort. Further will this be investigated in the subgroup of children and adolescents and those who have been hospitalized due to the virus infection.
Cafusertib (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c. Patient to receive escalating dose of cafusertib hydrochloride.
Investigators will conduct a radomized cross-over trial. 24 Preterm babies will be sampled, and to account for attrition, 26 preterm babies will be enrolled. Preterm babies born at less than 37 weeks of gestation will be included in the study. For each of the twelve-hour periods, they will be randomized to either manually controlled oxygen or automated oxygen control. After 12-hour periods, they will be shifted to alternate interventions. The total duration will be 24 hours. Written consent will be obtained from the parent/guardian before recruitment.

Block randomization will be done to randomize the babies. SLE 6000 ventilators will be used, and settings will be adjusted by the clinical team as per the clinical condition of the baby.

The Radical neonatal pulse oximeter (Masimo) is used to automatically adjust FiO2 in order to maintain SpO2 within a designated target range. Before turning on oxygen, FiO2 is manually adjusted to achieve SpO2 in the target range. Once stable SpO2 is achieved in TR, oxygen is turned on, which then adjusts FiO2 to keep SpO2 within target range. The FiO2 changes and their frequency are determined by the SpO2 trend, whether the SpO2 is above, below, or within the target range, and all changes are proportionate to the baseline FiO2 level. The pulse oximeter's settings will include normal sensitivity, an average time of 2-4 seconds, a 20-second alarm delay, and an alarm limit of 89% and 95% SpO2. Whenever feasible, the right wrist is used to apply the Masimo neonatal probe. The user will be advised on screen if the SpO2 signal will be lost. Oxygenie would display in blue, waiting for a signal, and would remain on the current FiO2 value for the first 60 seconds. After this point, if the SpO2 is within TR, it will continue at the current FiO2 level. If the SpO2 is above the TR and the FiO2 is 10% above the reference range, it will slowly decrease to the reference value. If SpO2 is below TR and FiO2 is more than 5% below the reference FiO2, then it will slowly increase to the reference level. The reference FiO2 value is updated every 30 minutes and is based on the last 60-minute average.
The utility model relates to an externally-applied paste for treating respiratory tract infection, belonging to medical components. Colloids are coated on one side of its basal body and a protective film is arranged on this side. A pharmaceutical layer which corresponds with the Tiantu acupoint of human body is arranged in the middle of the protective film and the basal body. Tablete Glycyrrhiza is arranged on one side of the pharmaceutical layer which is adjacent to the basal body and is coated with an antelope horn powder layer. While in use, please tear off the protective film and put the pharmaceutical layer exactly to the Tiantu acupoint and plaster it. The utility model device has the advantages that it has low cost, fast curative effect and it is convenient in use. It is mainly applicable to treat respiratory tract infections of tracheitis, pharyngitis and cough, etc. resulted by a cold. Besides, it is particularly suitable to the use of children.
The emergency department (ED) is on the front lines of the overdose epidemic, treating an increasing number of people with substance use disorders (SUD). In the year after a substance use-related ED visit, risk of death is six time higher than other patients, and for people treated after an opioid overdose, more than one in twenty patients will die. Each substance use-related ED visit represents a crucial opportunity to link patients to recovery services, however there are significant gaps in service provision with less than one in three receiving behavioral counseling and only one in five linked to addiction treatment. To improve linkage to recovery and addiction treatment services from the ED, study investigators launched a multidisciplinary, ED community health worker-peer recovery specialist program (PCHW), the Substance Misuse Assistance Response Team (SMART), at a large, academic, urban medical center which cares for the majority of patients with SUDs in Rhode Island. Drawing from models of existing peer recovery specialist, CHW, and health promotion advocate programs, SMART is a novel ED-based program that provides people with a substance-use related ED visit individualized support, short term case management, navigation to social services, harm reduction, recovery, and addiction treatment services in and out of the ED. SMART distinguishes itself from other models of ED patient navigation and/or peer recovery specialist programs by working in and out of the ED and focusing on social determinants of recovery. In recent years there has been a proliferation of ED peer recovery programs, but little is known about their effectiveness. Study investigators will conduct a pragmatic, mixed methods study of an established ED PCHW program to evaluate program delivery, linkage to evidence-based recovery services, and short- and long-term patient outcomes. Aims of this study are to 1) understand participant experiences working with a SMART PCHW and identify possible mechanisms for successful recovery linkage; 2) Evaluate SMART effectiveness on patient-centered outcomes, building recovery capital, and recovery linkage; 3) Evaluate SMART implementation and effectiveness on patient outcomes over time. Participant interviews will examine participant experiences with SMART, recovery services engagement, and identify potentially effective engagement strategies. A RE-AIM framework will be used to evaluate program implementation (process outcomes) and effectiveness (patient outcomes). Surveys and data linkage to hospital and state administrative databases will be used to measure changes in recovery capital, social networks, receipt of social services, linkage to harm reduction, recovery, and addiction treatment services, and changes in acute care utilization and mortality among people receiving SMART. Results from this study will provide robust data about ED peer recovery specialist program process and patient-level outcomes needed for a subsequent multilevel, comprehensive study to identify and test effectiveness of ED peer recovery program components and implementation strategies for program enhancement, dissemination, and sustainability.
Each neonate will be tested for blood glucose level twice on the same heel stick site using two glucose meters. additional 200-300 ul blood will be collected and centrifuged. Plasma will be tested blood glucose in the lab analyzer in the clinical laboratory.
The present invention provides a modified influenza viruses comprising haemagglutinin and a headless haemagglutinin. The haemagglutinin is provided by a source exogenous to the virus and the headless haemagglutinin is encoded by the viral genome. The present disclosure also provides modified influenza viruses comprising a headless haemagglutinin. The present disclosure also provides vaccine compositions comprising the modified influenza viruses. The vaccine compositions of the present disclosure can elicit broad neutralizing antibodies and provide cross-protection across various influenza strains. Methods, compositions and cells for propagating the modified influenza viral strains related to vaccines is also provided.